NMN

After oral ingestion, NMN is thought to be converted to NAD+ largely after first being broken down to nicotinamide riboside (NR) by gut enzymes and then re-synthesized, or absorbed via a dedicated transporter (Slc12a8) identified in mouse intestinal cells — whether an equivalent efficient transporter exists and is significant in humans is still debated in the research literature, which matters for how directly oral NMN reaches cells intact versus being processed through the same pathway as NR.

Human randomized trials of NMN, generally small and short-duration to date, have consistently shown it raises blood NAD+ levels and is well tolerated at studied doses (commonly 250–1,250 mg/day). Some trials report modest improvements in specific measures — for example, a 2021 trial in postmenopausal women with prediabetes (Yoshino et al., published in Science) found improved insulin sensitivity in skeletal muscle after 10 weeks of 250 mg/day NMN, though without significant change in several other metabolic markers measured.

No published human trial has shown NMN extends lifespan, reverses a hallmark of aging, or improves hard clinical outcomes — the human evidence base to date is limited to NAD+ level changes and scattered, generally small biomarker findings in specific populations. NMN is regulated as a dietary supplement in some markets, but its regulatory status has shifted in the U.S. after the FDA determined NMN was excluded from the dietary supplement definition due to its prior investigation as a drug, a status some manufacturers have disputed; check current regulatory status before purchase.